MCID: MLG039
MIFTS: 28

Malignant Essential Hypertension malady

Genetic diseases, Cardiovascular diseases, Blood diseases, Rare diseases categories

Aliases & Classifications for Malignant Essential Hypertension

About this section

Aliases & Descriptions for Malignant Essential Hypertension:

Name: Malignant Essential Hypertension 10 65
 
Accelerated Essential Hypertension 10


Classifications:



External Ids:

Disease Ontology10 DOID:10823
NCIt42 C34802
SNOMED-CT59 1218009, 78975002
ICD9CM29 401.0

Summaries for Malignant Essential Hypertension

About this section
MalaCards based summary: Malignant Essential Hypertension, also known as accelerated essential hypertension, is related to hypotrichosis-deafness syndrome and skin pilomatrix carcinoma. An important gene associated with Malignant Essential Hypertension is KLKB1 (Kallikrein B, Plasma (Fletcher Factor) 1), and among its related pathways are Antigen Presentation- Folding, assembly and peptide loading of class I MHC and Agents Acting on the Renin-Angiotensin System Pathway, Pharmacodynamics.

Related Diseases for Malignant Essential Hypertension

About this section

Diseases in the Familial Hypertension family:

Hypertension, Essential Hypertension, Essential 7
Hypertension, Essential 8 Benign Essential Hypertension
malignant essential hypertension Benign Secondary Hypertension
Malignant Hypertension Malignant Secondary Hypertension

Diseases related to Malignant Essential Hypertension via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 83)
idRelated DiseaseScoreTop Affiliating Genes
1hypotrichosis-deafness syndrome10.3HBB, HBD
2skin pilomatrix carcinoma10.3HBB, HBD
3fetal hemoglobin quantitative trait locus 110.2HBB, HBD
4proliferative fasciitis10.2HBB, HBD
5brucella melitensis brucellosis10.2HBB, HBD
6mediastinum neurofibroma10.2HBB, HBD
7mediastinum rhabdomyosarcoma10.2HBB, HBD
8large cell carcinoma with rhabdoid phenotype10.2HBB, HBD
9hepatocellular adenoma10.2HBB, HBD
10goiter10.2HBB, HBD
11avoidant personality disorder10.2HBB, HBD
12diffuse cutaneous mastocytosis10.2HBB, HBD
13adrenal gland disease10.2REN, TNFRSF25
14cold-induced sweating syndrome10.1ARSE, HLA-B
15idiopathic membranous glomerulonephritis10.1ACE, REN
16hyposmia nasal hypoplasia hypogonadism10.1ACE, REN
17primary hyperoxaluria10.1ACE, REN
18hypertension, diastolic10.1ACE, REN
19arteriosclerosis10.1
20aneurysm10.1
21hypobetalipoproteinaemia ataxia hearing loss10.1ACE, REN
22fibrosing mediastinitis10.1ACE, REN
23renal hypertension10.1ACE, REN
24postinfectious encephalomyelitis10.1HLA-A, HLA-B
25jaccoud's syndrome10.1HLA-A, HLA-B
26bladder papillary clear cell adenocarcinoma10.1HLA-A, HLA-B
27meninges hemangiopericytoma10.1HLA-A, HLA-B
28anthracosis10.1HLA-A, HLA-B
29childhood cerebellar astrocytic neoplasm10.1HLA-A, HLA-B
30acneiform dermatitis10.1HLA-A, HLA-B
31perinephritis10.1ACE, REN
32monocular esotropia10.1HLA-A, HLA-B
33hilar cholangiocellular carcinoma10.1HLA-A, HLA-B
34equatorial staphyloma10.1HLA-A, HLA-B
35xanthogranulomatous pyelonephritis10.1HLA-A, HLA-B
36iris disease10.1HLA-A, HLA-B
37acute gonococcal salpingitis10.1HLA-A, HLA-B
38human herpesvirus 810.1HLA-A, HLA-B
39carotid stenosis10.1HLA-A, HLA-B
40mhc class i deficiency10.1KLKB1, KNG1
41noonan syndrome 210.1HLA-A, HLA-B
42malignant iris melanoma10.1ACE, REN
43detrusor sphincter dyssynergia10.1HLA-A, HLA-B
44renal tubular dysgenesis10.1ACE, REN
45rectosigmoid cancer10.1HLA-A, HLA-B
46hordeolum10.1HLA-A, HLA-B
47multicentric reticulohistiocytosis10.1ACE, REN
48cytoplasmic body myopathy10.1HLA-A, HLA-B
49churg-strauss syndrome10.1HLA-A, HLA-B
50monocular exotropia10.1HLA-A, HLA-B

Graphical network of the top 20 diseases related to Malignant Essential Hypertension:



Diseases related to malignant essential hypertension

Symptoms for Malignant Essential Hypertension

About this section

Drugs & Therapeutics for Malignant Essential Hypertension

About this section

Drugs for Malignant Essential Hypertension (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
VerapamilapprovedPhase 211252-53-92520
Synonyms:
(+-)-Verapamil
(+/-)-VERAPAMIL
(1)-3-(3,4-Dimethoxyphenyl)-6-((5,6-dimethoxyphenethyl)methylamino)hexane-3-carbonitrile
2-(3,4-Dimethoxyphenyl)-5-[2-(3,4-dimethoxyphenyl)ethyl-methyl-amino]-2-(1-methylethyl) pentanenitrile
2-(3,4-dimethoxyphenyl)-5-[2-(3,4-dimethoxyphenyl)ethyl-methylamino]-2-propan-2-ylpentanenitrile
2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile
5-((3,4-Dimethoxyphenethyl)methylamino)-2-(3,4-dimethoxyphenyl)-2-isopropylvaleronitrile
5-[(3,4-Dimethoxyphenethyl)methylamino]-2-(3,4-dimethoxyphenyl)-2-isopropylvaleronitrile
52-53-9
56949-77-0
AB00053495
AC-16016
AC1L1DV5
Akilen
Anpec
Apo-Verap
Arpamyl
Arpamyl LP
BPBio1_000268
BRD-A09533288-001-02-7
BRD-A09533288-003-05-6
BSPBio_000242
BSPBio_001513
BSPBio_002358
Berkatens
Bio-0754
Bio1_000425
Bio1_000914
Bio1_001403
Bio2_000233
Bio2_000713
C07188
C27H38N2O4
CCRIS 6749
CHEBI:9948
CHEMBL6966
CID2520
CP-16533-1
CP-165331
Calan
Calan SR
Calan Sr
Calan sr
Calaptin
Calaptin 240 SR
Calcan
Cardiabeltin
Cardiagutt
Cardibeltin
Cardioprotect
Caveril
Civicor
Civicor Retard
Coraver
Cordilox
Cordilox SR
Corpamil
Covera-HS
Covera-Hs
Covera-hs
D-365
D02356
DB00661
Dexverapamil
Dignover
Dilacoran
Dilacoran HTA
DivK1c_000399
Drosteakard
Durasoptin
EINECS 200-145-1
EINECS 260-462-6
Elthon
FT-0080127
Falicard
Finoptin
Flamon
Geangin
HMS1791L15
HMS1989L15
HMS2089H17
Harteze
Hexasoptin
Hexasoptin Retard
Hormitol
I06-0063
IDI1_000399
IDI1_033983
Ikacor
Ikapress
Inselon
Iproveratril
Isoptimo
Isoptin
Isoptin Retard
Isoptin SR
Isoptin sr
Isoptine
Isoptino
Isotopin
Izoptin
Jenapamil
KBio1_000399
KBio2_000233
KBio2_002343
KBio2_002801
KBio2_004911
KBio2_005369
KBio2_007479
KBio3_000465
KBio3_000466
KBio3_002823
KBioGR_000233
 
KBioGR_001372
KBioGR_002343
KBioSS_000233
KBioSS_002346
L001330
LS-174
Lekoptin
Lodixal
Lopac0_001237
Magotiron
Manidon
Manidon Retard
MolPort-000-721-258
NCGC00016083-14
NCGC00024710-04
NCGC00024710-05
NCGC00024710-06
NCGC00024710-07
NCGC00024710-08
NCGC00024710-09
NCI60_020143
NINDS_000399
NSC272366
NU-Verap
Novapamyl LP
Novo-Veramil
Nu-Verap
Ormil
Praecicor
Prestwick0_000141
Prestwick1_000141
Prestwick2_000141
Prestwick3_000141
Quasar
Rapam
Robatelan
SID104171262
SID124881789
SID124881790
SPBio_001820
SPBio_002181
STK538085
Securon
Spectrum2_001740
Spectrum4_000906
Spectrum5_001786
Tarka
UNII-CJ0O37KU29
Univer
Univex
VERAPAMIL
Vasolan
Vasomil
Vasopten
Vera-Sanorania
Verabeta
Veracaps SR
Veracim
Veracor
Verahexal
Veraloc
Veramex
Veramil
Verapamil
Verapamil (USAN/INN)
Verapamil AL
Verapamil Acis
Verapamil Atid
Verapamil Basics
Verapamil Ebewe
Verapamil HCl
Verapamil Henning
Verapamil Hydrochloride
Verapamil Injection
Verapamil MSD
Verapamil NM
Verapamil NM Pharma
Verapamil Nordic
Verapamil PB
Verapamil Riker
Verapamil SR
Verapamil Verla
Verapamil [USAN:BAN:INN]
Verapamil [USAN:INN:BAN]
Verapamil [Usan:Ban:Inn]
Verapamil-AbZ
Verapamilo
Verapamilo [INN-Spanish]
Verapamilum
Verapamilum [INN-Latin]
Verapin
Verapress 240 SR
Veraptin
Verasal
Verasifar
Veratensin
Verdilac
Verelan
Verelan PM
Verelan Pm
Verelan SR
Verexamil
Veroptinstada
Verpamil
Vetrimil
Vortac
Vérapamil
alpha-((N-Methyl-N-homoveratryl)-gamma-aminopropyl)-3,4-dimethoxyphenylacetonitrile
alpha-(3-((2-(3,4-Dimethoxyphenyl)ethyl)-methylamino)propyl)-3,4-dimethoxy-alpha-(1-methylethyl)benzeneacetonitrile
alpha-Isopropyl-alpha-((N-methyl-N-homoveratryl)-gamma-aminopropyl)-3,4-dimethoxyphenylacetonitrile
cMAP_000023
delta-365
nchembio.368-comp2
nchembio.79-comp5
2
HydroxyureaapprovedPhase 2181127-07-13657
Synonyms:
1-HYDROXYUREA
127-07-1
4-03-00-00170 (Beilstein Handbook Reference)
55291_FLUKA
AC1L1GF8
AC1Q4ZXK
AI3-51139
BB_SC-7256
BRN 1741548
BSPBio_002164
Bio1_000451
Bio1_000940
Bio1_001429
Biosupressin
C07044
CCRIS 958
CHEBI:44423
CHEMBL467
CID3657
Carbamohydroxamic Acid
Carbamohydroxamic acid
Carbamohydroximic Acid
Carbamohydroximic acid
Carbamohydroxyamic Acid
Carbamohydroxyamic acid
Carbamoyl Oxime
Carbamoyl oxime
Carbamyl Hydroxamate
Carbamyl hydroxamate
Carrbamoyl Oxime
D00341
D006918
DB01005
DRG-0253
DivK1c_000556
Droxia
Droxia (TM)
Droxia (TN)
E0723DBA-5AF3-49D1-B5F6-59420AB87AC9
EINECS 204-821-7
EU-0100596
FT-0083575
H 8627
H0310
H20210
H8627_SIGMA
HMS1920F09
HMS2091L17
HMS501L18
HSDB 6887
HU
HYDREA (TN)
HYDROXY-UREA
Hidrix
Hidroxicarbamida
Hidroxicarbamida [INN-Spanish]
Hydrea
Hydrea (TM)
Hydrea, Biosupressin, Cytodrox, Hydroxyurea
Hydreia
Hydroxicarbamidum
Hydroxycarbamid
Hydroxycarbamide
Hydroxycarbamide (JAN/INN)
Hydroxycarbamidum
Hydroxycarbamidum [INN-Latin]
Hydroxycarbamine
Hydroxyharnstoff
Hydroxyharnstoff [German]
Hydroxylurea
Hydroxyurea
Hydroxyurea (D4)
Hydroxyurea (USP)
Hydroxyurea [USAN:BAN]
Hydroxyurea(d4)
 
Hydura
Hydurea
I05-0250
IDI1_000556
Idrossicarbamide
Idrossicarbamide [DCIT]
Idrossicarbamide [Dcit]
KBio1_000556
KBio2_001389
KBio2_003957
KBio2_006525
KBio3_001384
KBioGR_000383
KBioSS_001389
LS-709
Litaler
Litalir
Lopac-H-8627
Lopac0_000596
MLS001332381
MLS001332382
MLS002153389
MolMap_000029
MolPort-000-003-971
Mylocel
N-(Aminocarbonyl) Hydroxyamine
N-Carbamoylhydroxylamine
N-HYDROXY UREA
N-Hydroxymocovina
N-Hydroxymocovina [Czech]
N-Hydroxyurea
NCGC00015520-01
NCGC00015520-02
NCGC00015520-07
NCGC00093974-01
NCGC00093974-02
NCGC00093974-03
NCGC00093974-04
NCGC00093974-05
NCI C04831
NCI-C04831
NCI60_002773
NCIMech_000139
NHY
NINDS_000556
NSC 32065
NSC32065
Onco-Carbide
Onco-carbide
Oncocarbide
Oxyurea
S-phase/G-1 interface inhibitor
S1896_Selleck
SK 22591
SMR000059149
SPBio_000247
SPECTRUM1500344
SQ 1089
SQ-1089
Siklos
Spectrum2_000064
Spectrum3_000462
Spectrum4_000012
Spectrum5_000836
Spectrum_000909
Sterile Urea
TL8000673
UNII-X6Q56QN5QC
Ureaphil
WLN: ZVMQ
carbamide oxide
hydroxyaminomethanamide
hydroxyurea
nchembio.573-comp3
nchembio.90-comp4
nchembio749-comp3
tetratogen: inhibits ribonucleoside diphosphate reductase
3Calcium, DietaryPhase 23529

Interventional clinical trials:

idNameStatusNCT IDPhase
1Combination of Hydroxyurea and Verapamil for Refractory MeningiomasCompletedNCT00706810Phase 2
2Assessing Blood Pressure Remotely in Childhood Cancer SurvivorsCompletedNCT02476162

Search NIH Clinical Center for Malignant Essential Hypertension

Genetic Tests for Malignant Essential Hypertension

About this section

Anatomical Context for Malignant Essential Hypertension

About this section

Animal Models for Malignant Essential Hypertension or affiliated genes

About this section

Publications for Malignant Essential Hypertension

About this section

Articles related to Malignant Essential Hypertension:

(show all 13)
idTitleAuthorsYear
1
Human leukocyte antigens and malignant essential hypertension. (9657633)
1998
2
Does non-malignant essential hypertension cause renal damage? A clinician's view. (9004097)
1996
3
Urinary kallikrein excretion is low in malignant essential hypertension. (1325521)
1992
4
Renal haemodynamics and comparative effects of captopril in patients with benign- or malignant-essential hypertension, or with chronic renal failure. (3301082)
1987
5
Predisposing factors for the development of malignant essential hypertension. (3662703)
1987
6
Prospective measurement of glomerular filtration rate and effective renal plasma flow during treatment of malignant essential hypertension. (6494086)
1984
7
Renal function as an indicator of prognosis in malignant essential hypertension. (7089493)
1982
8
Immunological changes in patients with previous malignant essential hypertension. (6110039)
1981
9
Vascular lesions of malignant essential hypertension. (5567174)
1971
10
Vascular lesions of malignant essential hypertension. (5567956)
1971
11
Vascular lesions of malignant essential hypertension. (5504381)
1970
12
Successful twin pregnancy after treatment of malignant essential hypertension. (13572832)
1958
13
Clinicopathologic conference; generalized arteriosclerosis; malignant essential hypertension with dissecting aneurysm of the artery and coronary occlusion. (15426209)
1950

Variations for Malignant Essential Hypertension

About this section

Expression for genes affiliated with Malignant Essential Hypertension

About this section
Search GEO for disease gene expression data for Malignant Essential Hypertension.

Pathways for genes affiliated with Malignant Essential Hypertension

About this section

Pathways related to Malignant Essential Hypertension according to GeneCards Suite gene sharing:

idSuper pathways (with members indented)ScoreTop Affiliating Genes
19.4HLA-A, HLA-B
2
Show member pathways
8.6ACE, KNG1, REN

GO Terms for genes affiliated with Malignant Essential Hypertension

About this section

Cellular components related to Malignant Essential Hypertension according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1hemoglobin complexGO:000583310.4HBB, HBD
2MHC class I protein complexGO:004261210.1HLA-A, HLA-B
3integral component of lumenal side of endoplasmic reticulum membraneGO:007155610.0HLA-A, HLA-B
4blood microparticleGO:00725629.5HBB, HBD, KNG1
5extracellular exosomeGO:00700627.1ACE, ARSE, HBB, HLA-A, HLA-B, KLKB1
6extracellular regionGO:00055766.9ACE, HBB, KLK4, KLKB1, KNG1, REN

Biological processes related to Malignant Essential Hypertension according to GeneCards Suite gene sharing:

(show all 13)
idNameGO IDScoreTop Affiliating Genes
1oxygen transportGO:001567110.4HBB, HBD
2antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independentGO:000248010.0HLA-A, HLA-B
3antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentGO:000248610.0HLA-A, HLA-B
4positive regulation of T cell mediated cytotoxicityGO:000191610.0HLA-A, HLA-B
5detection of bacteriumGO:001604510.0HLA-A, HLA-B
6protection from natural killer cell mediated cytotoxicityGO:00422709.9HLA-A, HLA-B
7beta-amyloid metabolic processGO:00504359.9ACE, REN
8blood coagulation, intrinsic pathwayGO:00075979.9KLKB1, KNG1
9angiotensin maturationGO:00020039.8ACE, REN
10regulation of blood pressureGO:00082179.3ACE, HBB, REN
11antigen processing and presentation of peptide antigen via MHC class IGO:00024749.2ACE, HLA-A, HLA-B
12proteolysisGO:00065089.0ACE, KLK4, KLKB1, REN
13blood coagulationGO:00075968.6HBB, HBD, KLKB1, KNG1

Molecular functions related to Malignant Essential Hypertension according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1oxygen transporter activityGO:000534410.3HBB, HBD
2TAP bindingGO:004697710.0HLA-A, HLA-B
3iron ion bindingGO:00055069.7HBB, HBD, KLKB1
4peptide antigen bindingGO:00426059.5HLA-A, HLA-B
5heme bindingGO:00200379.5HBB, HBD, KLKB1
6receptor bindingGO:00051027.8HLA-A, HLA-B, KNG1, REN

Sources for Malignant Essential Hypertension

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet